is there a role for discontinuing treatment after prolonged androgen suppression?
OBJECTIVES: To determine the hormonal (luteinizing hormone [LH], testosterone) and biochemical (prostate-specific antigen [PSA]) response to withdrawal of LH-releasing hormone (LHRH) agonist therapy for patients with prostate cancer with an undetectable PSA who received this treatment for an extended period. METHODS: Four selected patients older than 70 years of age with advanced adenocarcinoma of the prostate who were treated with a depot injection of LHRH and antiandrogen therapy had their treatment discontinued. During the period of total androgen blockade, each patient obtained and maintained a persistent undetectable PSA level. After cessation of androgen blockade, patients underwent serum measurements of PSA and testosterone at baseline and then every 6 months for 36 months. Serum LH was performed at baseline and then at 6, 18, and 36 months. RESULTS: At the time androgen ablative therapy was discontinued, patients had received LHRH agonist/antiandrogen therapy for a mean of 108
